Screener
Jazz Pharmaceuticals JAZZ Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Non-cash interest expense | 4.7 | 17.1 |
| Deferred tax benefit | (66.2) | (43.8) |
| Gain on sale of priority review voucher | (122.8) | — |
| Other non-cash transactions | 3.9 | (6.5) |
| Changes in assets and liabilities: | ||
| Accounts receivable | (6.5) | 66.0 |
| Inventories | (77.8) | (35.6) |
| Prepaid expenses and other assets | 51.9 | 41.4 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's other income (expense)?
- Jazz Pharmaceuticals (JAZZ) reported other income (expense) of -$3.9M in Q1 2026.
- How has Jazz Pharmaceuticals's other income (expense) changed year-over-year?
- Jazz Pharmaceuticals's other income (expense) decreased by 160.0% year-over-year, from $6.5M to -$3.9M.
- What is the long-term trend for Jazz Pharmaceuticals's other income (expense)?
- Over 2 years (2021 to 2024), Jazz Pharmaceuticals's other income (expense) has grown at a 33.9% compound annual growth rate (CAGR), from -$10.03M to -$17.98M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Jazz Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude